Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From McKesson Corp.
McKesson’s exit from the space forced sponsors to switch vendors managing their REMS programs, which in some instances affected patient access to drugs. Omnibus legislation requires GAO report and collection of public input on factors FDA should consider in reviewing vendor changes.
US distribution giant McKesson has reached a nine-figure settlement deal with shareholders to resolve a class action lawsuit alleging that it participated in a price-fixing and anticompetitive scheme for generic drugs with manufacturers and other wholesalers.
As states weigh their options, the history of past settlements will be a factor. One state signed onto the settlement with the distributors but opted out of the deal with J&J, netting it millions more, and with faster payment, than it would have received under the national settlement.
Teva to pay $4.25bn over 13 years under agreement in principle with 12 state attorneys general, Native American tribes and plaintiffs’ lawyers. Previous settlement offer provided mostly medication. Deal is contingent on governments signing on and Allergan inking settlement.
- Medical Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.